CSL在伊利诺伊州投资1.5B美元,创造300个就业机会,使美国等离子体能加工稀有疾病治疗。 CSL to invest $1.5B in Illinois, creating 300 jobs and enabling U.S. plasma processing for rare disease treatments.

澳大利亚生物制药公司CSL将投资15亿美元,到2031年扩建其伊利诺伊州Kankakee设施,创造300个高技能工作和800个建筑职位。 Australian biopharmaceutical company CSL will invest $1.5 billion to expand its Kankakee, Illinois, facility by 2031, creating 300 high-skilled jobs and 800 construction positions. 该项目将使美国能够进行端到端等离子体处理,促进罕见疾病和免疫缺陷的救生疗法的生产。 The project will enable end-to-end plasma processing in the U.S., boosting production of life-saving therapies for rare diseases and immune deficiencies. 这些治疗依赖捐助者的血浆,对有终身需要的病人至关重要。 These treatments rely on plasma from donors and are critical for patients with lifelong needs. 这一扩展得到伊利诺伊州EDGE税收抵免计划的支持,并经过多年的基础设施升级规划。 The expansion is supported by Illinois’ EDGE tax credit program and follows years of planning to upgrade infrastructure. CSL在7年内为美国业务投资了30亿美元,其中包括300个等离子体中心。 CSL has invested $3 billion in U.S. operations over seven years, including 300 plasma centers. 官员们强调该区域的长期经济和医疗利益。 Officials highlight long-term economic and medical benefits for the region.